Regeneron Pharmaceuticals (REGN) stock
Health Care · Biotechnology
Regeneron Pharmaceuticals (REGN) is a Biotechnology company in the Health Care sector, headquartered in Tarrytown, New York. As of October 23, 2026, REGN closed at $805.02, a market capitalization of $82.88 billion, the 150th largest company in the S&P 500. Over the last twelve months it generated $15.53 billion in revenue (+17% year over year) and $3.58 billion in free cash flow. The stock trades at 19.9x trailing earnings and 12.8x forward earnings.
- 1-year total return: +40.6% (dividends reinvested)
- 5-year return: +7.3% a year
- 52-week range: $575.93 – $859.34
- Gross margin 44.5%, operating margin 33.1%
- Dividend yield: 0.47%
- FI Handbook report card: B+ across 10 metrics
- 21st largest of 60 Health Care stocks in the S&P 500
REGN price chart
1Y price change: +39.8% (price only; total returns below include dividends)
| Total return | 1M | YTD | 1Y | 3Y | 5Y | 10Y | MAX |
|---|---|---|---|---|---|---|---|
| REGN | +0.4% | +4.7% | +40.6% | +0.7% | +7.3% | +8.4% | +10.8% |
Dividends reinvested. 3Y and longer are annualized; MAX is annualized since 1991.
REGN key statistics
- Market cap
- $82.9B
- #150 in S&P 500
- P/E (TTM)
- 19.9x
- Forward P/E
- 12.8x
- EPS (TTM)
- $40.44
- Revenue (TTM)
- $15.5B
- +17%
- Free cash flow
- $3.6B
- Gross margin
- 44.5%
- Operating margin
- 33.1%
- Return on equity
- 14.0%
- Dividend yield
- 0.47%
- 52-week range
- $575.93 – $859.34
- Beta
- 0.15
- Price / sales
- 5.3x
- EV / EBITDA
- 16.0x
- Debt / equity
- 0.09x
- Employees
- 15,410
REGN report card
B+Ten fundamentals graded A to F against fixed thresholds. Not a buy or sell rating.
- Revenue growth16.7%B
- Gross margin44.5%B
- Operating margin33.1%A
- FCF margin23.0%B
- Return on equity14.0%C
- Net debt / EBITDA-1.1xA
- Forward P/E12.8xA
- PEG ratio1.3xB
- Shareholder yield4.6%B
- Share count change / yr-1.2%B
Regeneron Pharmaceuticals financials
Revenue went from $4.9B in fiscal 2016 to $14.3B in fiscal 2025, growing 12.8% a year.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.9B | $5.9B | $5.1B | $6.6B | $8.5B | $16.1B | $12.2B | $13.1B | $14.2B | $14.3B |
| Gross profit | $4.7B | $5.7B | $4.9B | $6.2B | — | — | — | — | — | — |
| Operating income | $1.3B | $2.1B | $2.5B | $2.2B | $3.6B | $8.9B | $4.7B | $4.0B | $4.0B | $3.6B |
| Net income | $895.5M | $1.2B | $2.4B | $2.1B | $3.5B | $8.1B | $4.3B | $4.0B | $4.4B | $4.5B |
| EPS (diluted) | $7.70 | $10.34 | $21.29 | $18.46 | $30.52 | $71.97 | $38.22 | $34.77 | $38.34 | $41.48 |
| Free cash flow | $974.0M | $1.0B | $1.8B | $2.0B | $2.0B | $6.5B | $4.4B | $3.9B | $3.7B | $4.1B |
| Buybacks | $0 | $0 | $4.4M | $275.9M | $5.8B | $1.6B | $2.1B | $2.2B | $2.6B | $3.4B |
| Dividends paid | — | — | — | — | — | — | — | $0 | $0 | $370.3M |
| Diluted shares | 116.3M | 115.9M | 114.8M | 114.6M | 115.1M | 112.2M | 113.5M | 113.7M | 115.1M | 108.6M |
Source: SEC filings (10-K XBRL). EPS and share counts are split-adjusted.
What's priced into REGN?
A reverse DCF asks what growth the current price requires. With an enterprise value of $77.6B and $3.6B of trailing free cash flow, Regeneron Pharmaceuticals needs to grow free cash flow about 12.6% a year for ten years (fading to 3.0% terminal growth) to earn a 10% annual return. For context, free cash flow grew 15.3% a year over the last five years.
P/E ratio history
Current 19.4x vs. median 28.3x (10th–90th percentile 14.2x–96.1x).
A model, not a forecast or advice. Small changes in assumptions move the answer a lot.
REGN dividend
- Dividend yield
- 0.47%
- Annual dividend
- $3.76
- Years of increases
- —
- 5-yr dividend growth
- —
- per year
- Payout ratio
- 9%
- Payments per year
- 4
Regular dividends per share by calendar year; special dividends excluded. Current year omitted until complete.
REGN analyst price targets
27 analysts' average 12-month target is $867.33 (+8% vs. $805.02). Targets range from $730.00 to $1,030. 68% rate it a buy.
REGN earnings
Next report: October 30, 2026. Regeneron Pharmaceuticals has beaten EPS estimates 5 quarters in a row. Last quarter's revenue was $4.3B (+17% year over year).
| Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Jul 30, 2026 | $10.21 | $14.29 | +40.0% |
| Apr 29, 2026 | $8.90 | $9.47 | +6.4% |
| Jan 30, 2026 | $10.75 | $11.44 | +6.4% |
| Oct 28, 2025 | $9.64 | $11.83 | +22.7% |
| Aug 1, 2025 | $8.44 | $12.89 | +52.7% |
| Apr 29, 2025 | $8.48 | $8.22 | -3.0% |
| Feb 4, 2025 | $11.19 | $12.07 | +7.8% |
| Oct 31, 2024 | $11.70 | $12.46 | +6.5% |
Stocks like REGN
| Name | Today | 1Y | Mkt cap | P/E | |
|---|---|---|---|---|---|
 ABBV AbbVie | +0.16% | +29% | $504.8B | 80.7x | Compare |
 AMGN Amgen | -1.79% | +54% | $237.5B | 27.3x | Compare |
 GILD Gilead Sciences | -0.73% | +32% | $193.5B | — | Compare |
 VRTX Vertex Pharmaceuticals Incorpor | -2.10% | +24% | $132.8B | 29.9x | Compare |
 MRNA Moderna | -1.25% | +662% | $79.9B | — | Compare |
 BIIB Biogen | -1.24% | +67% | $37.0B | 44.5x | Compare |
 INCY Incyte | -1.04% | +30% | $23.5B | 14.7x | Compare |
 LLY Eli Lilly and | -2.54% | +56% | $1.1T | 42.7x | Compare |
REGN news
- Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) · Oct 25, 2026
- 1 safe-and-steady stock with exciting potential and 2 facing headwinds · Oct 23, 2026
- Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release · Oct 23, 2026
- Are You Overpaying For Regeneron Stock Versus Its Rivals? · Oct 21, 2026
- Strong Dupixent Trajectory Anchors Regeneron Pharmaceuticals’ (REGN) Solid Financial Results · Oct 20, 2026
REGN stock FAQ
What is REGN's market cap?
Regeneron Pharmaceuticals's market capitalization is $82.88 billion as of October 23, 2026, ranking 150th in the S&P 500.
What is REGN's P/E ratio?
REGN trades at a trailing price-to-earnings ratio of 19.9x and a forward P/E of 12.8x. Its median P/E over the period we track is 28.3x.
Does REGN pay a dividend?
Yes. Regeneron Pharmaceuticals pays $3.76 per share a year, a 0.47% yield.
How much has REGN stock returned?
Including reinvested dividends, REGN returned +40.6% over one year, +7.3% a year over five years, +8.4% a year over ten years through October 23, 2026.
Is REGN stock overvalued?
At today's price, a reverse discounted cash flow model (10% discount rate, 3% terminal growth) implies Regeneron Pharmaceuticals must grow free cash flow about 13% a year for the next decade. Its free cash flow grew 15% a year over the last five years. Whether that is achievable decides if the stock is cheap or expensive. This is a model, not advice.
What is the REGN price target?
27 analysts cover REGN with an average 12-month price target of $867.33, +8% from the current price. 68% of them rate it a buy.
When does REGN report earnings?
Regeneron Pharmaceuticals is expected to report earnings on October 30, 2026. It has beaten EPS estimates 5 quarters in a row.
How many employees does Regeneron Pharmaceuticals have?
Regeneron Pharmaceuticals has about 15,410 full-time employees, or $1.0 million of revenue per employee.
Sources: SEC EDGAR filings, Yahoo Finance market data (delayed), FI Handbook calculations. Last close October 23, 2026. Methodology